-
Product Insights
New![]()
Net Present Value Model: Denali Therapeutics Inc’s DNL-343
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PH-284 in Cancer Anorexia-Cachexia Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PH-284 in Cancer Anorexia-Cachexia Syndrome Drug Details: PH284 is under development for wasting syndrome...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Alzheimer's Disease Drug Details:DNL-788 is under development for the treatment of Alzheimer’s disease, amyotrophic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Primary Progressive Multiple Sclerosis (PPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:DNL-788 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INCB-86550 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INCB-86550 in Melanoma Drug Details:INCB-86550 is under development for the treatment of advanced solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:DNL-788 is under development for the treatment of...
-
Product Insights
![]()
Denali National Park Bridge – Alaska
Equip yourself with the essential tools needed to make informed and profitable decisions with our Denali National Park Bridge - Alaska report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the Denali National...
-
Product Insights
![]()
Denali Com Ppty/ Epic Games/ Turnbridge Equities – Carolina Yard Mixed-Use Development – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Denali Com Ppty/ Epic Games/ Turnbridge Equities - Carolina Yard Mixed-Use Development - North Carolina report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Company Profile
![]()
Denali Therapeutics Inc – Company Profile
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. Its proprietary drug delivery platform technologies include an antibody transport vehicle and an enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other...
Add to Basket -
Company Profile
![]()
AbCellera Biologics Inc – Company Profile
AbCellera Biologics Inc (AbCellera) is a biotechnology company that discovers and develops next-generation therapeutic antibodies. The company’s single-cell platform helps in discovering rare antibodies by combining proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence and laboratory automation technology. AbCellera ultra-deep screening of single B cells allows access to immune responses which enables isolation of large and diverse panels of high antibodies from any species. The company works in partnership with Pfizer, Merck, GSK, Teva Pharmaceutical, Kodiak Sciences, Denali...
Add to Basket -
Thematic Analysis
![]()
Environmental Trends in Foodservice – Thematic Intelligence
This report analyzes the impact of environmental pressures on the Foodservice Sector. Who Should Buy Senior executives and ESG executives in Foodservice industry.
-
Product Insights
![]()
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy. The Mucopolysaccharidosis type II (MPS II) (Hunter Syndrome) pipeline market research report  provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis...
-
Product Insights
![]()
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Symptoms include abnormal bones in the spine, claw hand, cloudy corneas, deafness and heart valve problems. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy. The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I...
-
Product Insights
![]()
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Mucopolysaccharidosis type III (MPS III) is also known as Sanfilippo syndrome. It is an inherited metabolic disease caused by the absence or malfunctioning of certain enzymes needed to break down molecules called glycosaminoglycans (GAG). Symptoms include seizures, hyperactivity, liver and spleen enlargement, severe diarrhea or constipation, and enlargement of tonsils and adenoids. Treatment includes enzyme replacement therapy (ERT). The MPS III pipeline market research report provides comprehensive information on the therapeutics under development for MPS III, complete with analysis by...
-
Product Insights
![]()
Net Present Value Model: DNL-151
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model DNL-151 Drug Details DNL-151 is under...
-
Product Insights
![]()
Net Present Value Model: DNL-310
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model DNL-310 Drug Details DNL-310 is under...
-
Product Insights
![]()
Net Present Value Model: DNL-343
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model DNL-343 Drug Details DNL-343 is under...
-
Product Insights
![]()
Net Present Value Model: DNL-788
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model DNL-788 Drug Details DNL-788 is under...
-
Product Insights
![]()
Net Present Value Model: DNL-593
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model DNL-593 Drug Details DNL-593 is under...
-
Product Insights
![]()
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein Drugs Development Market Report Overview Alpha-synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.